Member Info for Laura2022

Last update

On the basis set out in the circular sent to shareholders on 14 December 2023 and in recent announcements, R&Q continues to work expeditiously towards achieving satisfaction of the conditions to enable that sale to take place.

 

R&Q continues to expect closing of that sale to occur in Q2 2024.

DNA damage repair and CRUK seem to suggest perhaps PYC will still help or has bene helping more recently?

From SAR 28th March 2024 interims

Company will now focus its resources on the clinical development of SDC-1801.

SRA737 (cancer)

SRA737 is a clinical-stage oral, selective Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.

· After the period end, on 2 January 2024, Sareum announced the Company's co-development partner, the CRT Pioneer Fund ("CPF"), has entered into a development and commercialisation licence agreement for SRA737 with a private biopharma company based in the United States.

· Under the terms of Sareum's co-development agreements with CPF and Cancer Research Technology Ltd, Sareum is entitled to receive 27.5% of any income arising from this licensing of the SRA737 programme.

Thanks to Debull for the below

The candidate was CCT245737, which was renamed PNT737, then licensed out to Sierra by which time it was SRA737 https://www.edisongroup.com/research/sierra-oncology-returns-rights-to-sra737/31442/ Sierra bought out by GSK and then SRA737 rights were returned to SAR after GSK's purchase of Sierra. Or something along those lines!

Thank goodness they're out

Now up 200% since buying at placing price

So pleasing for us all

High chance PYC will be helping with SAR trials THIS Q2

Yes

The 2 big movers willbe SND and RQIH

Also a large insurance company would maybe be circling at this juncture

If you look at the charts and the expectation of the news it suggested 3.5/4p should break today

Lots of big buys all yesterday

Great summary Smartmoney

In todays APTA RNS

Targeted delivery to specific cell populations is showing increasing use across the pharmaceutical sector, as it holds the potential for increased efficacy and reduced side effects from medications. Exemplar publicised partnerships for specifically targeted precision medicine developments include Ionis Pharmaceuticals Inc. licensing a single delivery vehicle from Bicycle Therapeutics Inc. for $45 million upfront, with additional milestone payments and royalties for each program developed under the collaboration; Partnering of Takeda Pharmaceutical with Peptidream Inc, with Peptidream Inc receiving up to $3.5 billion excluding royalty payments for delivery vehicles targeting the central nervous system. Both these deals demonstrate the urgent requirement and high values associated with developments and assets of this nature in the sector for successful targeting delivery vehicles.

Thanks Hopist

Anyone else finsing this?

One month into Q2....so chances are getting high now of an intra day RNS

Big movement soon judging by the chart ..very oversold

£3000 maximum buy

I agree

Across AIM similar directors are extorting £200k-300k salaries from funds amd just look at 100s of AIM stocks (eg CHLL today where CEO sacked for insider trading )

PYC directors pledged 2yrs ago to not have any pay rise until profotbale and Jim has not had pay rise for 5yrs

PYC mgmt have strong moral ethics imho

Difficult buying on Friday,let's see if that continues today ?

These 2 conferences cover 23rd to 28th April,should be a good opportunity to win new clients/contracts

Physiomics’ objective is to meet with leaders of early-stage/emerging biotech companies developing therapeutics in oncology and other indications to identify opportunities where quantitative pharmacology and PKPD modelling expertise can be applied to derisk their drug development journey.

Thanks for the link Ralph

Physiomics’ Head of Business Development, Hayley Close will be attending the event which brings together over 400 experts in the field of immuno-oncology to discuss the latest advancements in the discovery & development of cancer immunotherapies. Physiomics will be looking to engage with pharma and biotech leaders developing cancer immunotherapies to identify opportunities where PKPD and QSP modelling techniques can help inform development of the next generation of IO drugs.

Yes Ant

Been difficult to buy for about 5 or 6 days now ( as in difficult to get quotes for 100k to 200k or goes to negotiate trade)